Since targeting the mTOR pathway is a part of the chemotherapy regimen for advanced kidney cancer patients [4], we next assessed whether the responsiveness to this agent was correlated with the extent of genomic aberrations at 3p and at 14q. The gene discussed is MTOR; the disease is kidney cancer.